Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Receivables (2016 - 2025)

Vanda Pharmaceuticals' Change in Receivables history spans 16 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 8.03% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $7.5 million, down 42.65%, while the annual FY2025 figure was $7.5 million, 42.65% down from the prior year.
  • Change in Receivables for Q4 2025 was $4.1 million at Vanda Pharmaceuticals, down from $5.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $9.1 million in Q2 2023 and bottomed at -$9.0 million in Q4 2021.
  • The 5-year median for Change in Receivables is $2.0 million (2021), against an average of $1.2 million.
  • The largest YoY upside for Change in Receivables was 662.42% in 2023 against a maximum downside of 829.85% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$9.0 million in 2021, then soared by 145.16% to $4.1 million in 2022, then increased by 18.79% to $4.8 million in 2023, then decreased by 8.37% to $4.4 million in 2024, then decreased by 8.03% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Change in Receivables are $4.1 million (Q4 2025), $5.6 million (Q3 2025), and $353000.0 (Q2 2025).